Effectiveness and Safety of High-Dose Biologics in Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance.

Colleen K CorrellPeter ShraderAnne DennosThomas PhillipsNatalie J Shiff Ruud H J VerstegenTimothy Beukelmannull null

Published in: Arthritis care & research (2021)

Dosing escalation appears to be a reasonable choice to improve disease control, however, large, prospective, randomized studies evaluating specific biologic agents are needed.

Keyphrases

juvenile idiopathic arthritis
high dose
rheumatoid arthritis
disease activity
open label
double blind
phase iii
low dose
stem cell transplantation
placebo controlled
phase ii
case control
clinical trial
early life
study protocol
randomized controlled trial
childhood cancer
young adults